Institut Paoli-Calmettes

What Institut Paoli-Calmettes does

Institut Paoli-Calmettes (IPC) is a French non-profit Comprehensive Cancer Center headquartered in Marseille, founded in 1923 and operating under French public health law as a Centre de Lutte Contre le Cancer within the Unicancer federation of 18 French cancer centers. The institution provides integrated oncology services across the full care continuum — prevention, diagnosis, medical oncology, surgical oncology (including robotic and minimally invasive surgery), radiotherapy, nuclear medicine, hematology and cell therapy, supportive care, and rehabilitation — serving adult, elderly, adolescent and young adult patients with all cancer types across southeastern France and beyond. It holds OECI Comprehensive Cancer Center accreditation, HAS certification with the 'Haute Qualité des soins' mention, ENETS Center of Excellence status, and serves as a national reference center for neuroendocrine tumors (RENATEN, TENpath) and as one of 25 reference centers in the NETSARC+ sarcoma network.

The center's technology stack centers on advanced diagnostics and therapeutics rather than a software platform: a Da Vinci Single Port (SP) robotic surgical system (first in the PACA region), the proprietary CINSARC molecular signature for soft tissue sarcoma prognosis, vectorized internal radiotherapy with LUTATHERA for neuroendocrine tumors, an INCa-labeled CLIP2 early-phase clinical trial unit, and a Centre de Ressources Biologiques holding 200,000+ biological samples (tissues, blood cells, serum, DNA, RNA) supporting translational research. Patient access is delivered through multi-modal channels including direct phone scheduling (Bureau des Rendez-Vous), physician-to-physician consultations, Doctolib online booking for selected services, IPC Connect telemedicine, and regional outreach consultations at four partner hospitals.

Revenue is generated primarily through French public health insurance (Sécurité Sociale) reimbursement under national fee schedules for the standard care activity, supplemented by institutional and pharmaceutical-funded clinical trial revenue (conducted as promoter or investigating center across INCa, European network, and industry partnerships), and private donations (eligible for 66% income tax, 75% IFI, and 60% corporate tax deductions). As a non-profit CLCC, IPC is not equity-financed and does not pursue capital-market growth; expansion is funded through operating surplus, public capital allocations, and philanthropic giving. Governance sits with Unicancer as the parent federation, with Pr Norbert VEY serving as Directeur général and Head of Hematology.

Name

Institut Paoli-Calmettes

Legal name

Institut Paoli-Calmettes

Website

https://institutpaolicalmettes.fr

Company type

Private

Founded year

1923

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Institut Paoli-Calmettes is a French non-profit Comprehensive Cancer Center in Marseille providing integrated oncology care, research, and prevention across all cancer types. It serves as a national and European reference center for rare tumors within the Unicancer federation of 18 French cancer centers.

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical and Diagnostic Laboratories (62151)

SIC

Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Site Data Management Support (EDC/Source/SDV Readiness) (HLAGACAL), Decentralized/Hybrid Trial Enablement (DCT) Platforms (HLACAOAL)

Keywords

• Cancer treatment services
• Oncology hospital
• Clinical research
• Radiation therapy
• Surgical oncology

Headquarters

HQ city

Marseille-en-beauvaisis

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others, Marketing or Sales

Revenue model

1. Public Healthcare Services: IPC operates as a public cancer center (Centre de Lutte Contre le Cancer) under the French public health code, providing cancer care services reimbursed through the French social security system (Sécurité Sociale). Patient payments are covered through public health insurance and complementary insurance.
2. Clinical Research: Revenue from clinical trials conducted as promoter or investigating center, funded by institutional grants, pharmaceutical partnerships, and government cancer research funding (INCa, European networks)
3. Private Donations: Private donations from individuals supporting cancer research and innovation programs. Donors can specify program preferences or leave allocation to IPC discretion. Tax deductions available (66% income tax, 75% IFI, 60% corporate tax)

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Core offering

Institut Paoli-Calmettes (IPC) is a Comprehensive Cancer Center providing integrated oncology care for adult cancer patients across the full spectrum: medical oncology (chemotherapy, immunotherapy, targeted therapy), surgical oncology (open, minimally invasive, robotic), radiation therapy and nuclear medicine (including LUTATHERA vectorized internal radiotherapy), hematology and stem cell transplantation, oncogenetics, and supportive care. As a Centre de Lutte Contre le Cancer (CLCC) within the Unicancer federation, IPC also conducts translational and clinical research (including early-phase trials under CLIP² label), maintains a 200,000+ sample Biological Resources Center, and runs prevention, training, and patient-education programs reimbursed through the French Sécurité Sociale public health insurance system.

Differentiator

Problem solved

Functional benefit

Products and services

• IPC Connect Telemedicine Platform Web and mobile application providing remote teleconsultations, secure access to medical records, and digital healthcare coordination for cancer patients and their physicians.
• Doctolib Online Appointment Booking Online scheduling service for new patients to book mammographies, breast ultrasounds, onco-urology consultations, and breast surgery appointments directly through the Doctolib platform.
• CLIP²-Certified Early-Phase Clinical Trials Program (ETOH) INCa-labeled Center for Early Phase Clinical Investigations in onco-hematology, conducting Phase 1 and Phase 2 oncology and hematology clinical trials for patients.
• Oncogenetic Counseling (DASC Department) Clinical oncogenetics service providing hereditary cancer risk assessment, genetic testing, family screening, personalized prevention plans, and targeted surveillance for patients with cancer predisposition syndromes (BRCA, Lynch, Li-Fraumeni, VHL, FAP, MEN).
• Adolescents and Young Adults (AJA) Oncology Program Specialized oncology care for patients aged 18-30 with cancer, including dedicated coordinator, multidisciplinary psychological and social support, adapted physical activity, fertility preservation, and educational and professional reintegration support.
• Oncogeriatric Care Service Multidisciplinary oncology care combining oncologists and geriatricians to address aging-related vulnerabilities, functional reserves, comorbidities, and treatment toxicity in elderly cancer patients.
• LUTATHERA Vectorized Internal Radiotherapy Specialized Radiothérapie Interne Vectorisée using LUTATHERA (lutetium-177) for neuroendocrine tumor treatment, available at IPC since 2016.
• Da Vinci Single Port (SP) Robotic Surgery Single-incision robotic surgery using the Da Vinci SP system for minimally invasive oncological procedures; IPC is the fourth establishment in France and first in PACA region to acquire this technology.
• DIEP Free Flap Breast Reconstruction Autologous breast reconstruction performed by microsurgery after mastectomy using the patient's own tissues via DIEP (Deep Inferior Epigastric Perforator) free flap technique.
• vNOTES Sentinel Lymph Node Procedure Minimally invasive gynecological surgery using the vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) approach for sentinel pelvic lymph node procedures.
• Patient Hotel Lodging Furnished apartment lodging near IPC for patients traveling more than 100 km for treatment, billed at 20 euros per night.
• In-Room Patient Television Subscription Paid bouquet of TV channels available in patient rooms at IPC, with a free internal IPC channel option.
• Photon Scanner Imaging Service New photon scanner installation project supporting cancer research and diagnosis, available as a research program supported by private donations.

Quantifiable outcome

• IPC ranked among best hospitals in France for multiple specialties in Le Point annual rankings
• +4 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

19 partnerships are on record, tiered flagship, core and minor.

• EURACAN (European Reference Network for Rare Adult Solid Cancers)flagshipStrategic or Co-development Partner · 1 December 2021European network of 66 establishments for rare adult solid cancers. IPC is reference center for neuroendocrine tumors (one of 4 centers in France). Mission: improve diagnosis, access to innovative care, and promote clinical trial cooperation for rare cancers.
• ENETS (European Neuroendocrine Tumor Society)flagshipStrategic or Co-development Partner · 1 January 2017European reference network with 57 centers across Europe. IPC holds Center of Excellence designation since 2017, re-evaluated every 5 years. The only CLCC in France with this designation. Enables access to expertise, innovation, and optimal multidisciplinary care for neuroendocrine tumors.
• RENATEN (Réseau National de prise en charge des Tumeurs Neuroendocrines)flagshipStrategic or Co-development Partner · 1 January 2010National network created under INCa leadership in 2010. Coordinates 23 regional competence centers across France, led by 4 national reference centers (IPC, Paris, Lyon). Objective: equitable specialized care and innovation access for all neuroendocrine tumor patients.
• IRCADcoreStrategic or Co-development PartnerPartnership with IRCAD (Institut de Recherche contre les Cancers de l'Appareil Digestif), a world reference for training in endoscopy and minimally invasive surgery. From April 2020, IPC oncological endoscopy training cases are conducted at IRCAD facilities.
• TENpath (réseau national d'anatomopathologie dédié aux tumeurs neuroendocrines)coreStrategic or Co-development PartnerNational pathology network dedicated to neuroendocrine tumors. IPC provides expert anatomopathological expertise and performs double readings of surgical specimens and biopsies for the region.
• Oncodistinct European NetworkcoreStrategic or Co-development PartnerEuropean oncology research network enabling IPC participation in international clinical trials and collaborative research across multiple cancer types.
• Segal Cancer Centre (Montréal, Canada)coreStrategic or Co-development PartnerInternational research partnership for cancer treatment and research collaboration between IPC Marseille and Segal Cancer Centre in Montreal, Canada.
• Moffitt Cancer Center (Florida, USA)coreStrategic or Co-development PartnerInternational research collaboration with Moffitt Cancer Center in Tampa, Florida, USA, focusing on cancer research and treatment innovations.
• Karolinska Institute (Sweden)coreStrategic or Co-development PartnerResearch partnership with Karolinska Institute in Sweden for international oncology research collaboration.
• TGEN-TD2 (Arizona, USA)coreStrategic or Co-development PartnerInternational research partnership with TGen (The Translational Genomics Research Institute) and TD2 in Arizona, USA for cancer research collaboration.
• Rui Jin Hospital (Shanghai, China)coreStrategic or Co-development PartnerResearch collaboration with Rui Jin Hospital in Shanghai, China for international oncology studies.
• Applied Research on Cancer (Verona, Italy)coreStrategic or Co-development PartnerInternational research partnership with ARC (Applied Research on Cancer) in Verona, Italy for cancer treatment and research collaboration.
• CRLC Antoine Lacassagne (Nice, France)coreStrategic or Co-development PartnerRegional partnership for neuroendocrine tumor care. Dr Eric François and Dr Claire Jaraudias from CRLC Antoine Lacassagne participate in weekly RCP RENATEN ENETS multidisciplinary meetings with IPC team.
• Institut St Catherine (Avignon, France)coreStrategic or Co-development PartnerRegional partnership for neuroendocrine tumor care. Dr Laurent Mineur and Dr Clémence Toullec from Institut St Catherine participate in weekly RCP RENATEN ENETS multidisciplinary meetings with IPC team.
• CHICAS Hôpital de GapminorChannel Partner/ Reseller/ DistributorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CHICAS Hôpital de Gap as part of IPC's regional outreach.
• CH de MartiguesminorChannel Partner/ Reseller/ DistributorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CH de Martigues as part of IPC's regional outreach.
• CHIPL Hôpital d'Aix en ProvenceminorChannel Partner/ Reseller/ DistributorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at CHIAP Hôpital d'Aix en Provence as part of IPC's regional outreach.
• Hôpital privé la CasamanceminorChannel Partner/ Reseller/ DistributorRegional partnership for oncogenetic consultations. Dr Jessica Moretta provides weekly advanced consultations at Hôpital privé la Casamance as part of IPC's regional outreach.
• NETSARC+ NetworkflagshipStrategic or Co-development PartnerINCa-labeled care and research network for sarcomas and connective tissue tumors. IPC is one of 25 reference centers in France. Network ensures quality diagnosis (expert pathology review) and treatment for sarcoma patients.

Scale indicators7 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Gustave Roussy: Gustave Roussy is the largest French Comprehensive Cancer Center and a fellow Unicancer CLCC. It is directly comparable to IPC in scope (multidisciplinary oncology, research, teaching) but operates at a national/international scale.
• Institut Curie: Institut Curie is a Paris-based comprehensive cancer center combining hospital care, research, and teaching. It is a direct peer to IPC in full-spectrum oncology, with additional historical strength in radiotherapy.
• Centre Léon Bérard: Centre Léon Bérard (Lyon) is a Unicancer CLCC providing comprehensive cancer care, research, and prevention. It is a direct peer to IPC with a similar service model and referral-network role in its region.
• Institut Bergonié: Institut Bergonié (Bordeaux) is a Unicancer CLCC with multidisciplinary oncology and research focus, including a strong sarcoma program. Direct peer to IPC, particularly in rare-tumor reference center activities.
• Institut de Cancérologie de l'Ouest (ICO): ICO is a French comprehensive cancer center with two sites (Angers, Saint-Herblain) providing oncology care, research, and prevention. Direct peer to IPC under the Unicancer network.
• IUCT-Oncopole: IUCT-Oncopole (Toulouse) is a French comprehensive cancer center integrating care, research, and innovation. Direct peer to IPC, with similar academic hospital integration and clinical research depth.
• Centre Georges-François Leclerc: Centre Georges-François Leclerc (Dijon) is a French CLCC offering comprehensive cancer treatment and translational research. Direct peer to IPC within the Unicancer federation.
• Centre François Baclesse: Centre François Baclesse (Caen) is a Unicancer CLCC delivering multidisciplinary oncology care and research. Direct peer to IPC in the French CLCC federation.

Regional players

• Karolinska Comprehensive Cancer Center: Karolinska is a leading European academic cancer center and an IPC research partner. It is a relevant European peer with similar comprehensive cancer center and translational research profile, but operates in Sweden.
• Moffitt Cancer Center: Moffitt is a US NCI-designated Comprehensive Cancer Center and an IPC research partner. Comparable in research and translational depth, but operates in the US healthcare system with different reimbursement dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/IPCclips
• Facebookfacebook.com/communication.ipc
• LinkedInlinkedin.com/company/institut-paoli-calmettes/?originalSubdomain=fr
• Instagraminstagram.com/p/DUklhbFDK4M/?img_index=1
• Xx.com/paoli_calmettes

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Institut Paoli-Calmettes